[Diabetic ketoacidosis in an HIV-infected patient undergoing antiretroviral therapy].
Following the introduction of highly active antiretroviral therapy (HAART), a number of metabolic and morphologic alterations, known as HIV-associated lipodystrophy syndrome (HALS), have been increasingly common in HIV-infected patients being treated with this therapy. The use of protease inhibitors (PI), in particular, has been associated with insulin resistance and hyperglycaemia, but only infrequently with diabetic ketoacidosis. We report a case of diabetic ketoacidosis in an HIV-infected woman after 1(1/2) years of a PI-containing regimen, demonstrating reduced beta cell function and insulin resistance.
Holm
Malene Rahbek
MR
H:S Hvidovre Hospital, Endokrinologisk Klinik, Infektionsmedicinsk Afdeling. malenerahbekholm@dadlnet.dk
Hansen
Birgitte Rønde
BR
Røder
Michael E
ME
D019380:Anti-HIV Agents / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy*; D006801:Humans; D007333:Insulin Resistance; D008875:Middle Aged; D011480:Protease Inhibitors / Q000009:adverse effects; D012307:Risk Factors
D019380:Anti-HIV Agents; D011480:Protease Inhibitors